BRADLEY HARDIMAN

Head of UK/EU Search & Evaluation, Astellas Pharmaceuticals

A biochemist by training, Bradley started his career working for the world’s largest pharmaceutical companies, driving drug discovery programmes. He has since spent 20 years commercialising research, mainly emanating from the world’s most prestigious universities. This experience includes seven and a half years within the seed funds team at Cambridge Enterprise (CE), the commercialisation arm of the University of Cambridge. Here, he made 16 investments in 12 different companies, ranging from therapeutics (including small molecules, biologics and gene therapy), diagnostics and prognostics, medical devices, reagents, digital health, and scientific instrumentation. 

Bradley currently heads up the UK/EU Search & Evaluation team at Astellas Pharmaceuticals. Here his team scouts for potential partnerships of interest to Astellas, including research collaborations, licensing, VC investing and M&A.

Bradley has an undergraduate degree in Medical Biochemistry from Brunel University, a research master’s degree in Molecular Biochemistry from the University of Cambridge and an Executive MBA from Bayes (formerly Cass) Business School. He is also a visiting business fellow at InnovationRCA, the commercialisation arm of the Royal College of Art.

17 May 2022
Leonardo Royal Hotel
London Tower Bridge

VIEW ON DEMAND